Stocks · News reference
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity is enormous.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that it has reached an
Filed: 2026-10-06 AccNo: 0001493152-26-045865 Size: 23 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
PRELIMINARY PROSPECTUSSubject to completion, dated September 25, 2026 751,879 Shares of Common Stock Pursuant to this prospectus, the selling stockholder identified herein (the "Selling Stockholder") is offering
NeOnc Technologies announced early clinical improvements in a critically ill three-year-old boy treated with investigational intranasal NEO100 through its Compassionate Care program in Abu Dhabi. The patient is now breathing independently without ventilator support and showing renewed leg movement. The company emphasized these observations involve a single patient and do not establish efficacy or predict outcomes in other patients.
Filed: 2026-10-15 AccNo: 0001829126-26-011189 Size: 237 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits